No mutation at codon 918 of the RET gene in a family with multiple endocrine neoplasia type 2B
- 1 December 1995
- journal article
- case report
- Published by Wiley in Clinical Endocrinology
- Vol. 43 (6), 759-762
- https://doi.org/10.1111/j.1365-2265.1995.tb00547.x
Abstract
Multiple endocrine neoplasia type 2B (MEN 2B) is a rare cancer syndrome which is inherited in an autosomal dominant manner. The molecular basis of this condition has recently been defined as a mutation of codon 918 of exon 16 of the RET proto-oncogene. The mutation in codon 918 has been described in 69 out of 72 families with MEN 2B. We have studied a brother and sister who undoubtedly have the features of MEN 2B as evidenced by medullary thyroid carcinoma, phaeochromocytoma, mucosal neuromas and skeletal abnormalities. Neither of these patients has the classic gene mutation at codon 918 of exon 16 of the RET proto-oncogene, and although exons 2-20 have also been sequenced, no abnormality has been found. DNA analysis is a sensitive method of screening families for the MEN 2 syndromes. The absence of the mutation at codon 918 in a phenotypically normal individual would refute the diagnosis of MEN 2B, but in an individual with some of the features of MEN 2B would make the clinician reconsider the diagnosis. This family demonstrates that, although it is rare, the absence of the mutation in codon 918 of exon 16 of the RET proto-oncogene does not always exclude the diagnosis of MEN 2B. In such families routine biochemical screening for medullary thyroid carcinoma and phaeochromocytoma must be maintained for all individuals at genetic risk.Keywords
This publication has 10 references indexed in Scilit:
- Genotype‐phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation ConsortiumJournal of Internal Medicine, 1995
- Mutation of the RET protooncogene in sporadic medullary thyroid carcinomaGenes, Chromosomes and Cancer, 1995
- Clinical Screening as Compared with DNA Analysis in Families with Multiple Endocrine Neoplasia Type 2ANew England Journal of Medicine, 1994
- Single missense mutation in the tyrosine kinasecatalytic domain of the RET protooncogene is associated with multiple endocrineneoplasia type 2B.Proceedings of the National Academy of Sciences, 1994
- Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumoursHuman Molecular Genetics, 1994
- Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes and Hirschsprung diseaseJournal of Cell Science, 1994
- A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinomaNature, 1994
- The Protein Kinase Family: Conserved Features and Deduced Phylogeny of the Catalytic DomainsScience, 1988
- Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkageNature, 1987
- A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10Nature, 1987